Tipifarnib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myelomonocytic, Chronic
Conditions
Leukemia, Myelomonocytic, Chronic
Trial Timeline
Jan 10, 2017 → Nov 30, 2020
NCT ID
NCT02807272About Tipifarnib
Tipifarnib is a phase 2 stage product being developed by Kura Oncology for Leukemia, Myelomonocytic, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT02807272. Target conditions include Leukemia, Myelomonocytic, Chronic.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myelomonocytic, Chronic were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04809233 | Pre-clinical | Active |
| NCT04865159 | Phase 1 | Terminated |
| NCT03719690 | Phase 2 | Completed |
| NCT02807272 | Phase 2 | Completed |
| NCT02779777 | Phase 2 | Terminated |
| NCT02464228 | Phase 2 | Completed |
| NCT02383927 | Phase 2 | Completed |
Competing Products
20 competing products in Leukemia, Myelomonocytic, Chronic